Biblio
Export 644 results:
Author [ Title] Type Year Filters: First Letter Of Last Name is N [Clear All Filters]
“Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
, “Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimer's Disease Patients Showing Neuropsychiatric Symptoms.”, J Alzheimers Dis, vol. 66, no. 3, pp. 993-999, 2018.
, “Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Cerebrovascular Disease and Neurodegeneration in Alzheimer's Disease with and without a Strong Family History: A Pilot Magnetic Resonance Imaging Study in Dominican Republic.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1519-1528, 2018.
, “Challenges and Considerations Related to Studying Dementia in Blacks/African Americans.”, J Alzheimers Dis, vol. 60, no. 1, pp. 1-10, 2017.
, “Change of Amyloid-β 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 63, no. 3, pp. 989-1002, 2018.
, “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
, “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
, “Changes in Neural Connectivity and Memory Following a Yoga Intervention for Older Adults: A Pilot Study.”, J Alzheimers Dis, vol. 52, no. 2, pp. 673-84, 2016.
, “Changes of Cerebrospinal Fluid Peptides due to Tauopathy.”, J Alzheimers Dis, vol. 58, no. 2, pp. 507-520, 2017.
, “Characterizing Limbic-Predominant Age-Related TDP-43 Encephalopathy Without Alzheimer's Disease and Lewy Body Dementia in the Oldest Old: A Case Series.”, J Alzheimers Dis, vol. 96, no. 1, pp. 113-124, 2023.
, “Chronic Cerebral Hypoperfusion Accelerates Alzheimer's Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model.”, J Alzheimers Dis, vol. 53, no. 3, pp. 893-905, 2016.
, “Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration.”, J Alzheimers Dis, vol. 56, no. 4, pp. 1505-1518, 2017.
, “Chronic Sleep Disturbances Alters Sleep Structure and Tau Phosphorylation in AβPP/PS1 AD Mice and Their Wild-Type Littermates.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1341-1355, 2023.
, “Chronic Traumatic Encephalopathy Presenting as Alzheimer's Disease in a Retired Soccer Player.”, J Alzheimers Dis, vol. 54, no. 1, pp. 169-74, 2016.
, “Chronic Traumatic Encephalopathy Presenting as Alzheimer's Disease in a Retired Soccer Player.”, J Alzheimers Dis, vol. 54, no. 1, pp. 169-74, 2016.
, “Chronic Traumatic Encephalopathy Presenting as Alzheimer's Disease in a Retired Soccer Player.”, J Alzheimers Dis, vol. 54, no. 1, pp. 169-74, 2016.
, “Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 151-63, 2016.
, “Circulating Cell-Free Genomic DNA Is Associated with an Increased Risk of Dementia and with Change in Cognitive and Physical Function.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1233-1240, 2022.
, “Circulating Progenitor Cells Correlate with Memory, Posterior Cortical Thickness, and Hippocampal Perfusion.”, J Alzheimers Dis, vol. 61, no. 1, pp. 91-101, 2018.
, “Classification of Depression, Cognitive Disorders, and Co-Morbid Depression and Cognitive Disorders with Perfusion SPECT Neuroimaging.”, J Alzheimers Dis, vol. 57, no. 1, pp. 253-266, 2017.
, “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
, “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
, “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
,